Not a stretch in this case and Ellis will remain as a consultant. Sherman has been here 10 years and did most of the talking in CC's. Market might react but in all due respect, already has the last few days.
rumrunner - The IBB cost you the 4K and many other BIOs were slaughtered Thursday and Friday. Maybe the BREXIT turnaround will give some of that back to us?
Are you implying that a good measure is starter scripts meaning that new patients all do starter scripts? Can't the good DR's order 10 day supplies if insurance (medicare) now covers w/o using starter kits? Also, are the paid RX's the total paid in May or do the exclude those that ordered 60-90 day supply in April? These scripts are hard to fully identify how many patients are actually on V since January (which could be a few).
sweeting or sweating? I pulled some money out of RLYP the last week and put it into dividend paying non-BIO stocks such as FDUS and SFL (Shipping). Not much mind you. I bought UCO (OIL/GAS ETF) below $10 awhile ago and now watching if it goes below $12 again. The play there is IF oil goes above $50 and gas above $3 then "good" things may happen. As far as Relypsa, I have a core but this market is just killing any BIO whether it has a approved drug or is in early phases of trials. Like you said Lurker, all about cash and "cash is king" in this market. DO NOT TRUST this market until it proves some consistency.
Are now significantly underwater. Add to that T Rowe P who bought in at $20+ about 7M shares. They are down at least $150M. The BOD is actually a pretty stellar group of leaders and success. IPLEX is not too far off anymore. Arikayce is now what the UBS guy (Roden) said last November - "a 2017 story". Unless we see a significant sell-off, we will recover if all else hold true but be sure to know NOBODY is happy right now except the shorts!
These are the times to write negative reports (even "lies") because the market is heavily leaning towards a down side. The bears are winning and those who used to believe in investing $'s on good stocks are getting beaten up. Therefore little trust is left (some panic sets in too). When or where does this stop. The FED can go fly on their interest rate hike. This market reflects the economy, mood and motivation of the world. too many negative things emphasized (and rightly so) and nothing much positive anymore.
Well, if we don't trust this psycho market, cash is at least safe. Hard to believe they have done another round of BIO beat downs after already changing the valuation rules.
marvin - IBB/XBI have dropped significantly the last 2 days so most BIOs took haircuts. INSM would be more severe but most of this is the IBB spiraling down.
And normally RLYP takes the big hit both days. PPS should be maybe $17.25-$17.50 but we have stood strong and went up to $19.75. Last Friday we said it was "covering" or nothing meaningful. Today we say? What does Berens say? Another hit piece and a downgrade?
med - By syaying the "CEO" you do mean the CEO, Senior Executives, the BOD and the major holders of stock (5% and above for starters). These "decisions" are not made by one individual. Hopefully Sam Islay (ORBIMED) and the other large stock holders put pressure on a sale if there truly are bidders.
Pharma - it's a MESSAGE BOARD - no intelligence required. Anybody can post any nonsense they want. All BIO market DD and stock logic is no longer useful in this "clown show". Just like some of the ANALysts we know and "love".
The underlying issue is the BIO market in general. The IBB just took a 20 pt hit in 3 days after climbing past 286 towards 300. So, all stocks associated with the IBB (most that is) have had a 30%+ haircut since last August. The market changed the rules and has discounted accordingly. Your house analogy actually occurred between late 2007 and beyond where a house that was assessed a $400K value became less than $300K. We do have the law of "supply and demand" working for us as BP till has to recover the loss of revenue de to the "patent cliff" effect on its stellar drugs (which now have competition). Veltassa is almost the perfect drug with so many obstacles passed in the last 8 months. This "new" market (HK/CKD) and other potential uses make this very attractive yet the BIO market has discounted significantly. Again, HOW could these other BP's bid between $2.3B and $2.7B for an UNAPPROVED drug last fall (which makes no sense) versus what Relypsa's veltassa potential and being approved in last October. Why are so many TUTES buying more shares or standing pat?
on his twitter site. Decent discussion going on there and many are recent TWEETS.
Some posted that AZN has just opened "stability" jobs that are TEMP starting 6/30/16 thru 6/30/17 wonder if that is related to a new ZS-9 stability study?
Even those that were "completed" were updated on the clinical trials site just recently. The ZS005 still says December, 2016 though. Maybe they were waiting for the PDUFA (5/26) to do so?